Summer Sale: Save 51% on Pro and invest smartly

[edd_has_expired_licenses]

Summer Sale: Save 51% on Pro and invest smartly

[/edd_has_expired_licenses]

Invitae’s Revenue by Segment (2016-2021)

Exclusive Data

You need the Pro Plan for unlimited access.

Pro Plan

$39 per month*

51% discount ends in:

00
Days
00
Hours
00
Mins.
00
Seconds

Exclusive Data

You need the Pro Plan for unlimited access.

Pro Plan

$39 per month*

51% discount ends in:

00
Days
00
Hours
00
Mins.
00
Seconds

Download

About

This statistic highlights Invitae’s Revenue by Segment from Q1 2016 onwards, split across Biopharma partner, Direct patients, Institutions, Insurance patients, and Other business to business segments.
Subscribe to Pro or Enterprise plans to unlock this feature.
More information
Subscribe to Pro or Enterprise plans to unlock this feature.
Contact the Analyst
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on reddit
Share on facebook
Share on twitter
Share on linkedin
Share on email

Become a smarter investor today.

Access Business Quant for as low as $19/month

Become a smarter investor today.

Access KPIs & Segment Financials on US stocks

This statistic highlights Invitae’s Revenue by Segment from Q1 2016 onwards, split across Biopharma partner, Direct patients, Institutions, Insurance patients, and Other business to business segments.

Invitae provides genetic testing services that assist patient care for a lifetime, from hereditary illness diagnosis, family planning, preventive healthcare screening, tailored diagnosis, therapy, and cancer monitoring. These tests are conducted through a unique platform, which rapidly expands to assist patients, healthcare professionals, biopharmaceutical firms, and other partners to gain wider potential of genetics and thus to increase their usage along the continuum. Invitae uses a unique design, process automation, robotics, and software solutions in the field of bioinformatics to achieve sample processing efficiency and complicated variant interpretation that enables medical interpretation on a scale. This resulted in a new and simpler approach to collect and use high-quality, accessible genetic information for crucial choices in healthcare.

Invitae’s Revenue by Segment

Segments Q1 2020 Q1 2021 YOY Growth Revenue Share in Q1 2021
Biopharma partner NA $13.72 NA 13.24%
Direct patient $5.79 $8.95 54.58% 8.64%
Institutions $13.50 NA NA NA
Insurance patient $43.79 $60.89 39.05% 58.76%
Other business to business $20.06 NA 19.36%
Total $63.08 $103.62 64.27% 100.00%

(All figures in millions, except percentages)

Invitae’s total revenue increased from $64.25 million in Q1 2020 to $103.63 million in Q1 2021, marking a 61.29% growth on a year-on-year basis.

Invitae Corporation’s revenue is further bifurcated into the following segments:

Biopharma partner

Invitae with Biopharma partners provides free testing to individuals who satisfy the requirements for particular diseases. Invitae’s strategy blends cutting-edge genetics with a large network of patients and physicians.

The Biopharma partner segment generated $13.72 million in Q1 2021 which accounted for 13.24% of the company’s total revenue. The revenue was declined from $31.55 million in Q4 2020.

Direct patient

Invitae’s revenue from the Direct patient segment increased from $5.79 million in Q1 2020 to $8,95 million in Q1 2021, a growth of 54.58% on a year-on-year basis. During this period, this segment contributed 8.64% to the company’s total revenue.

Institutions

The Institutions segment generated $13.50 million in Q1 2020 which accounted for 13.24% of the company’s total revenue. The revenue was declined from $31.55 million in Q4 2020.

Insurance patient

The majority of Invitae’s revenue was generated through the insurance patient segment accounting for 58.76% of the company’s t0tal revenue in Q1 2021, amounting to $60.89 million. It grew by 39.05% compared to $443.79 million earned in Q1 2020.

Other business to business

The Other business-to-business (B2B) segment generated $20.06 million in Q1 2021 which accounted for 19.36% of the company’s total revenue.

Company Overview

Locus Development, Inc. was incorporated in the state of Delaware On January 13, 2010, and later renamed Invitae Corporation in 2012. Sean George is the current CEO of the company. It is headquartered in San Francisco, California, United States. The company employed 2100 people by the end of March 2021. Invitae has acquired Good Start Genetics and CombiMatrix in 2017. It also announced the acquisition of ArcherDX in 2020 for $1.4 billion. Invitae Corporation was created as a subsidiary of Genomic Health. Its common stocks are listed on the New York Stock Exchange under the ticker ‘NVTA’.

Invitae Corporation faces tough competition from Natera, Quest Diagnostics, Bio-Reference Laboratories, Ambry Genetics, and Progenity.

Did you like Invitae’s Revenue by Segment statistic?

Access thousands of more such key performance indicator data points, on listed companies, with Business Quant.

You can also get started for free.

Read more

Access Segment financials and KPI data on US stocks

Our Plans

Always know what you’ll pay. No hidden costs or surprises.

  • Annual
  • Monthly

Basic

Get to know us

  • Access basic data
  • No credit card required
$0
per month
Start for Free

51% discount until September 30

Pro

For serious investing

  • Granular KPI data Access segment financials, non-GAAP metrics and KPI data from presentations and filings. Examples include financials by segment / region / product category, AT&T's broadband subscriber trends, Tesla's deliveries by model and lots more.
  • Stock research tools Features include : Stock screener, Stock comparison, sector financials, stock warnings, advanced charting tools, financial statements dating back 10+ years, stock reports, SEC filings and stock ratings. There are 200+ financial items and ratios on thousands of US stocks.
  • Industry data & tools Access premium operating data on 40+ industries. Examples include market share, smartphone shipments by vendor, subscribers by wireless carrier, historical gold production. There are 20,000+ such statistics.
$39
$19
per month*
Buy Now

Enterprise

For tailored workflows

  • All of Pro plan Get unfettered access to all our dashboards and dossiers.
  • Custom built features Get tailored dashboards built specially for you , based on your set of requirements, to simplify your research workflow.
$99
per month, onwards*
Contact Us

* Billed annually, local taxes extra. 

Basic

Get to know us

  • Access basic data
  • No credit card required
$0
per month
Start for Free

51% discount on Annual plan

Pro

For serious investing

  • Granular KPI data Access segment financials, non-GAAP metrics and KPI data from presentations and filings. Examples include financials by segment / region / product category, AT&T's broadband subscriber trends, Tesla's deliveries by model and lots more.
  • Stock research tools Features include : Stock screener, Stock comparison, sector financials, stock warnings, advanced charting tools, financial statements dating back 10+ years, stock reports, SEC filings and stock ratings. There are 200+ financial items and ratios on thousands of US stocks.
  • Industry data & tools Access premium operating data on 40+ industries. Examples include market share, smartphone shipments by vendor, subscribers by wireless carrier, historical gold production. There are 20,000+ such statistics.
$39
per month*
Buy Now

Enterprise

For tailored workflows

  • All of Pro plan Get unfettered access to all our features.
  • Custom built features Get tailored dashboards built specially for you , based on your set of requirements, to simplify your research workflow.
$99
per month, onwards*
Contact Us

* Local taxes extra. 

BQ Star 51% off

Get Pro for 51% off

  • Access all features immediately
  • Datasets updated every day
  • Export data in CSV and XLSX formats

Offer Ends In

Starting from $39 $19 / month

.